Neuroendocrine gastro-enteropancreatic tumors – from eminence based to evidence-based medicine – A Scandinavian view
- 8 April 2015
- journal article
- review article
- Published by Informa UK Limited in Scandinavian Journal of Gastroenterology
- Vol. 50 (6), 727-739
- https://doi.org/10.3109/00365521.2015.1033001
Abstract
Neuroendocrine tumors (NETs) comprise a heterogenous group of neoplasms with variable clinical expression and progression. The primary tumors most frequently occur in the lungs, intestine and the pancreas. The NET incidence is approximately 6.1/100,000 per year with a prevalence higher than 35/100,000 per year. A NET may be functioning with symptoms related to hormone overproduction or non-functioning, not presenting any hormone-related symptoms. From the early 1980s and onwards, Uppsala University Hospital has contributed significantly to diagnosis, just to mention immunohistochemistry, radio-immunoassays for hormones and peptides and molecular imaging. On the therapeutic side, treatments with cytotoxics as well as biologicals such as, somatostatin analogs and interferons have been evaluated. We have furthermore been involved in important phase III trials for registration of so called, new targeted agents such as, RADIANT-3 and RADIANT-2. Our group were also the first to localize the gene for MEN I on chromosome 11 locus q13. Most recent developments have been the establishments of new biomarkers such as, olfactory receptor E51E1 as well as micro-RNAs in carcinoid tumors of the intestine and lung. A new oncolytic virus, Ad-Vince, for treatment of most NETs has been developed and is ready for the clinic. Furthermore, we have been involved in establishing Nordic and international collaborations. Today, NETs is an area with rapid development and recognized by international organizations at conferences, with large attendance. The Nordic countries continue to be significant contributors to the field.Keywords
This publication has 93 references indexed in Scilit:
- Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumorsLaboratory Investigation, 2013
- Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)Theranostics, 2012
- Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patientsLaboratory Investigation, 2010
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideJournal of Clinical Oncology, 2010
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumoursBritish Journal of Cancer, 2010
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid TherapyClinical Cancer Research, 2007
- IMMUNOASSAY OF ENDOGENOUS PLASMA INSULIN IN MANObesity Research, 1996
- Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumoursEuropean Journal Of Cancer, 1992
- Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid SyndromeNew England Journal of Medicine, 1983